These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28692178)

  • 1. Cell-free DNA - Minimally invasive marker of hematological malignancies.
    Kubaczkova V; Vrabel D; Sedlarikova L; Besse L; Sevcikova S
    Eur J Haematol; 2017 Oct; 99(4):291-299. PubMed ID: 28692178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
    Soscia R; Della Starza I; De Novi LA; Ilari C; Ansuinelli M; Cavalli M; Bellomarino V; Cafforio L; Di Trani M; Cazzaniga G; Fazio G; Santoro A; Salemi D; Spinelli O; Tosi M; Terragna C; Robustelli V; Bellissimo T; Colafigli G; Breccia M; Chiaretti S; Di Rocco A; Martelli M; Guarini A; Del Giudice I; Foà R
    Hematol Oncol; 2023 Feb; 41(1):50-60. PubMed ID: 36251440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cell-free DNA in haematological malignancies.
    Lim JK; Kuss B; Talaulikar D
    Pathology; 2021 Apr; 53(3):416-426. PubMed ID: 33648721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
    Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Circulating Tumor DNA in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Promises and Challenges.
    Xue Y; Xia X; Liu X; Zheng Y; Gu H; Wang X
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):86. PubMed ID: 38420833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
    Deshpande S; Tytarenko RG; Wang Y; Boyle EM; Ashby C; Schinke CD; Thanendrarajan S; Zangari M; Zhan F; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Eur J Haematol; 2021 Feb; 106(2):230-240. PubMed ID: 33107092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of Liquid Biopsy for Lung Cancer Treatment.].
    Mori S; Yatabe Y
    Rinsho Byori; 2016 May; 64(4):407-411. PubMed ID: 29182807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA.
    Thakral D; Gupta R; Sahoo RK; Verma P; Kumar I; Vashishtha S
    Front Cell Dev Biol; 2020; 8():604391. PubMed ID: 33363162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA in the Management of Colorectal Cancer.
    Harlé A
    Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies.
    Giudice V; Ianniello M; De Novellis D; Pezzullo L; Petrillo N; Serio B; D'Addona M; Della Corte AM; Rizzo M; Cuffa B; Castaldi MA; Savarese P; Mori A; Castiello R; Fico A; Savarese G; Selleri C
    Clin Exp Med; 2024 Apr; 24(1):69. PubMed ID: 38578383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
    Barbosa A; Peixoto A; Pinto P; Pinheiro M; Teixeira MR
    Expert Rev Mol Med; 2018 Dec; 20():e6. PubMed ID: 30558693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
    Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
    Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
    Ikeda S; Schwaederle M; Mohindra M; Fontes Jardim DL; Kurzrock R
    J Hematol Oncol; 2018 Jun; 11(1):76. PubMed ID: 29866143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.
    Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E; Fotiou D; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e905-e909. PubMed ID: 32723621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
    Sánchez R; Ayala R; Martínez-López J
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
    Vrabel D; Sedlarikova L; Besse L; Rihova L; Bezdekova R; Almasi M; Kubaczkova V; Brožová L; Jarkovsky J; Plonkova H; Jelinek T; Sandecka V; Stork M; Pour L; Sevcikova S; Hajek R
    Eur J Haematol; 2020 Mar; 104(3):190-197. PubMed ID: 31763708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.